EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
AbbVie's Temab-A Earns FDA Breakthrough Therapy Designations In CRC, NSCLC;Stock Up
AbbVie's Telisotuzumab Adizutecan Secures Dual FDA Breakthrough Therapy Designations
AbbVie (NYSE:ABBV) Hits New 12-Month High on Analyst Upgrade - Stock Observer
Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?
AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%
AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold?
AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%
Forget Bonds: How Retirees Collect $6,650 a Month From Dividends Alone
AbbVie Inc. $ABBV Stock Sold by Hall Laurie J Trustee - Daily Political
Prediction: LLY Has Another Massive Growth Opportunity Beyond Weight Loss
Abbvie-Genmab Epkinly data signal first-line filing for DLBCL
Immunotherapeutic targeting of calreticulin mutant myeloproliferative neoplasms
Scotiabank Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock
$100,000 in 5 Dividend Kings Will Generate Close to $4,000 Each Year Safely
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News
AbbVie (NYSE:ABBV) Releases Q3 2026 Earnings Guidance
Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug | Morningstar
Genmab and AbbVie's Epcoritamab Treatment Significantly Reduces Blood Cancer Progression Risk, ETPharma
AbbVie Inc. (ABBV) Stock: Phase 3 Lymphoma Trial Cuts Progression Risk 51%
AbbVie (NYSE:ABBV) Stock Price Up 1.2% - Still a Buy?
Genmab stock surges 11% on positive cancer drug trial data
Park National Corp OH Sells 6,771 Shares of AbbVie Inc. $ABBV
AbbVie Inc. $ABBV Position Lowered by Eastern Bank
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
AbbVie (NYSE:ABBV) Stock Jumps 1.2% - Still a Buy? - Daily Political
AbbVie Inc. $ABBV Stock Position Lessened by MassMutual Private Wealth & Trust FSB
Best Pharmaceutical Stocks To Add to Your Watchlist - October 4th - Stock Observer
Is AbbVie (ABBV) Still Undervalued On FDA Approval And Fresh Pipeline Data?
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
Pharmaceutical Stocks To Watch Now - October 3rd - Zolmax
5 High-Yield Dividend Stocks to Buy for October Income with Cash Flow to Spare
AbbVie Just Won FDA Approval for a Once-Daily Parkinson's Pill. Here's Why It Matters More Than You Think.
Biotech Stocks To Watch Now - October 2nd - Daily Political
Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories
AbbVie (NYSE:ABBV) Stock Jumps 1.3% - Here's What Happened
How Much Does a 58-Year-Old Need Invested to Replace a $160,000 Salary With Dividends?
CX Institutional Cuts Stock Position in AbbVie Inc. $ABBV - Daily Political
Biotech Stocks To Watch Now - October 2nd - Zolmax
Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease
RINVOQ Drives Continued Skin Repigmentation Through Week 76 In AbbVie Studies
HRSA discloses manufacturers approved for revised 340B rebate pilot
5 Solid Dividend Stocks to Buy Now
AbbVie to Host Third-Quarter 2026 Earnings Conference Call | Morningstar
5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test)
RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)
What Does AbbVie (ABBV) Need To Prove After Its Eczema Drug And AI Update?
AbbVie To Present New Dermatology Data At 2026 EADV Congress
Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson
AbbVie Inc. (ABBV) Stock: Rebounds as Zumilokibart Shows Strong Skin and Itch Improvement Results
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
AbbVie Reports Positive Phase 2 Results For Zumilokibart In Atopic Dermatitis
AbbVIe's Zumilokibart Meets Phase 2 Goal In Atopic Dermatitis Study
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 | Morningstar
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress | Morningstar
AbbVie (NYSE:ABBV) Shares Down 1% - Should You Sell?
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval
AbbVie Partners With Valkai To Advance AI-powered Clinical Research
Allergan Aesthetics receives Health Canada authorization for Boey® (trenibotulinumtoxinE), the first and only rapid-onset, short-duration neurotoxin for frown lines
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Analysts
FDA Nod For JUVMO Parkinson's Drug Could Be A Game Changer For AbbVie (ABBV)
Is AbbVie (ABBV) A Bargain After FDA Approval Of JUVMO For Parkinson's?
Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial
Should FDA Approval Require Action From AbbVie (ABBV) Investors?
Johnson & Johnson's Next Growth Engine Is Taking Shape
AbbVie Wins FDA Approval For JUVMO In Parkinson's Disease
Kodiak soars on double phase III win in wet AMD
AbbVie Won FDA Approval for Parkinson's Pill Juvmo. Here's Why Management Already Expects a Slow Start
AbbVie lands FDA approval for next-generation Parkinson's drug, Juvmo
AbbVie (ABBV) Stock: FDA Greenlights Innovative Parkinson's Treatment Juvmo - Blockonomi
AbbVie Gets FDA OK of Juvmo for Parkinson's Disease | Morningstar
AbbVie Announces FDA Approval Of JUVMO For Parkinson's Disease
US FDA approves AbbVie's drug for Parkinson's disease
Abbvie's Juvmo FDA approval brings new Parkinson's option | BioWorld
International practice patterns and beliefs concerning intravenous methylprednisolone and low-dose aspirin in giant cell arteritis
AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth
How to Build $7,250 a Month in Dividend Income Without Owning a Single Yield Trap
What Does AbbVie (ABBV) Need To Prove With Its Latest Pipeline Moves?
Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study
AbbVie (ABBV) Wins A New Lymphoma Nod, Is The Stock Still Cheap?
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study
ADARx Pharmaceuticals raises $446 million in upsized IPO
ADARx prices upsized Nasdaq IPO at top
RNAi drug specialist ADARx raises $446M IPO
AbbVie's EPKINLY Receives Health Canada Approval For Follicular Lymphoma
Rep. Pete Sessions Sells Off Shares of Apple Inc. (NASDAQ:AAPL)
EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma | INN
Ulcerative Colitis Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | ABNewswire
QRG Capital Management Inc. Increases Stake in AbbVie Inc. $ABBV
Envestnet Portfolio Solutions Inc. Raises Stock Position in AbbVie Inc. $ABBV
Latest news
Show more
Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty
September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations
Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge
